What is Petros Pharmaceuticals Inc's earnings per share (EPS)?

Petros Pharmaceuticals Inc (PTPI) reported diluted earnings per share of -$1.56 for fiscal year 2025. This represents a 98.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Petros Pharmaceuticals Inc (PTPI) Financials

PTPI

FY2025 annual

Revenue Not reported for FY2025

Net Income $1.9M +113.4% YoY

EPS (Diluted) -$1.56 +98.1% YoY

Operating Cash Flow -$6.7M -158.7% YoY

Market Cap $280K as of Sep 10, 2026

Price / Sales n/m no revenue reported

Price / Earnings 0.1x on $1.9M net income, FY2025

Price / Book 0.4x on $701K equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PTPI SEC filings page.

This page shows Petros Pharmaceuticals Inc (PTPI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PTPI FY2025 2026-08-29

Capital transactions repaired the balance sheet while operations remained cash-negative and FY2025 accounting profit diverged from underlying operating performance.

The apparent FY2025 profit was not operating earnings: net income was $1.9M despite an operating loss of -$4.6M. Operating cash flow of -$6.7M reinforces that reported profit did not reflect cash-generating operations, implying below-operating-line items drove the difference.

FY2024 ended with negative equity of -$7.5M, but FY2025 ended with positive equity of $2.9M. That reversal occurred alongside $8.2M of financing cash inflow, so balance-sheet repair appears linked to capital transactions rather than operating cash generation.

Operating cash flow worsened from -$2.6M in FY2024 to -$6.7M in FY2025, showing that the latest cash-generation trend deteriorated even as the balance sheet improved. Reported liquidity equaled 9.2 months of annual operating outflow, making it a snapshot of available resources rather than evidence of a self-funding business.

Financial Health Signals

Financial health score not available

Petros Pharmaceuticals Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

4/6

Petros Pharmaceuticals Inc passes 4 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

$3.52used

For every $1 of reported earnings, Petros Pharmaceuticals Inc used $3.52 of operating cash (-$6.7M OCF vs $1.9M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.

Interest Coverage At Risk

N/A

Petros Pharmaceuticals Inc reported an operating loss of $4.6M against $257K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income

-$956K

YoY-117.6%

QoQ+3.2%

Petros Pharmaceuticals Inc reported -$956K in net income in Q2 2026. This represents a decrease of 117.6% from the same quarter a year earlier. Against the prior quarter it is up 3.2%.

EPS (Diluted)

-$0.30

YoY+75.0%

Petros Pharmaceuticals Inc earned -$0.30 per diluted share (EPS) in Q2 2026. This represents an increase of 75.0% from the same quarter a year earlier.

Revenue

Not reported for Q2 2026.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$3.5M

YoY-52.4%

QoQ-19.8%

5Y CAGR-20.6%

Petros Pharmaceuticals Inc held $3.5M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

42M

YoY0.0%

5Y CAGR+33.9%

Petros Pharmaceuticals Inc had 42M shares outstanding in Q2 2026. That is unchanged from the same quarter a year earlier.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-136.3%

YoY-258.5pp

QoQ-80.6pp

Petros Pharmaceuticals Inc's ROE was -136.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 258.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 80.6 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

None of these metrics is reported for Q2 2026.

PTPI Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PTPI quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Revenue	N/A	N/A	$5.1M-12.2%	$5.8M-2.8%	$6.0M-23.3%	$7.8M-18.3%	$9.6M
Cost of Revenue	N/A	N/A	$1.2M-25.7%	$1.6M-28.7%	$2.3M+43.1%	$1.6M-60.5%	$4.0M
Gross Profit	N/A	N/A	$3.9M-7.0%	$4.2M+13.2%	$3.7M-40.4%	$6.2M+12.7%	$5.5M
R&D Expenses	N/A	N/A	$2.6M+8.5%	$2.4M+38.4%	$1.7M-2.7%	$1.8M+289.1%	$460K
SG&A Expenses	N/A	$4.6M+0.3%	$4.6M-50.0%	$9.3M-24.1%	$12.2M-21.7%	$15.6M-0.5%	$15.7M
Operating Income	N/A	-$4.6M-0.3%	-$4.6M+66.0%	-$13.6M+31.6%	-$19.9M-10.3%	-$18.0M-4.4%	-$17.3M
EBITDA	N/A	N/A	-$1.8M+82.6%	-$10.3M+27.8%	-$14.3M-28.2%	-$11.2M-5.2%	-$10.6M
Interest Expense	N/A	$257K-54.2%	$561K+4.6%	$536K-10.0%	$596K+61.7%	$369K-87.9%	$3.1M
Income Tax	N/A	$0	$0	$0	N/A	$0+100.0%	-$1.4M
Net Income	N/A	$1.9M+113.4%	-$14.3M-75.4%	-$8.2M+59.3%	-$20.0M-123.0%	-$9.0M+56.3%	-$20.6M
EPS (Basic)	N/A	-$1.56+98.1%	-$83.47-1214.5%	-$6.35+34.4%	-$9.68-17.3%	-$8.25-114.3%	-$3.85
EPS (Diluted)	$0.03	-$1.56+98.1%	-$83.47	-$6.35	-$9.68	-$8.25	-$3.85
Diluted Shares (Avg)	N/A	28M+8642.0%	321,042	2M	2M	1M	5M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$725K	$1.6M-5.9%
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$265K	$287K-29.7%
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	$461K	$1.3M+1.8%
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	$102K	$588K+51.2%
SG&A Expenses	$989K-45.1%	$1.0M-29.6%	N/A	$991K-17.3%	$1.8M+33.5%	$1.5M-3.0%	$578K	$1.2M-40.2%
Operating Income	-$989K+45.1%	-$1.0M+29.6%	N/A	-$991K+17.3%	-$1.8M-33.5%	-$1.5M+3.0%	-$578K	-$1.2M+75.1%
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	$79K	-$458K+88.5%
Interest Expense	$32K-64.0%	$40K-16.0%	N/A	$67K-11.6%	$89K-25.6%	$48K-68.5%	$214K	$76K-42.3%
Net Income	-$956K-117.6%	-$987K+56.3%	N/A	-$923K+58.4%	$5.4M+920.6%	-$2.3M-4.5%	-$9.3M	-$2.2M+51.2%
EPS (Basic)	-$0.30+75.0%	-$0.03+99.7%	$0.39+133.6%	-$0.03+99.8%	-$1.20+87.0%	-$9.37+77.8%	-$1.16+46.5%	-$16.65-484.2%
EPS (Diluted)	-$0.30+75.0%	-$0.03	$0.39+133.6%	-$0.03	-$1.20	-$9.37	-$1.16	-$16.65
Diluted Shares (Avg)	47M+82.8%	46M	N/A	42M	26M	1M	N/A	393,192

Not reported in any period shown, so not listed: Income Tax.

PTPI Balance Sheet

PTPI quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Total Assets	$5.2M-51.4%	$10.6M-68.5%	$33.8M+4.2%	$32.4M-51.9%	$67.4M-3.5%	$69.9M
Current Assets	$5.2M-29.2%	$7.3M-64.2%	$20.4M+39.0%	$14.7M-52.0%	$30.5M+17.9%	$25.9M
Cash & Equivalents	$5.1M+198.9%	$1.7M-87.1%	$13.3M+41.5%	$9.4M-60.5%	$23.8M+39.1%	$17.1M
Short-Term Investments	$0	$0	$0	$0	$0	$0
Inventory	N/A	$1.3M-16.2%	$1.6M-11.3%	$1.8M+249.3%	$520K-31.7%	$761K
Accounts Receivable	N/A	$416K-81.3%	$2.2M+5.5%	$2.1M-14.1%	$2.5M-52.4%	$5.2M
Long-Term Investments	$0	$0	$0	$0	$0	$0
Total Liabilities	$2.3M-87.3%	$18.1M-15.1%	$21.3M+35.6%	$15.7M-50.6%	$31.8M-39.2%	$52.4M
Current Liabilities	$2.3M-87.3%	$18.0M+67.4%	$10.8M+52.4%	$7.1M-77.2%	$31.0M-26.1%	$41.9M
Non-Current Liabilities	$0-100.0%	$75K-99.3%	$10.5M+21.9%	$8.7M+900.1%	$865K-91.8%	$10.5M
Total Equity	$2.9M+138.4%	-$7.5M-161.9%	$12.1M-27.7%	$16.7M-53.0%	$35.5M+103.5%	$17.5M
Retained Earnings	-$111.3M+1.7%	-$113.2M-14.5%	-$98.9M-9.0%	-$90.7M-28.3%	-$70.7M-14.6%	-$61.7M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$3.5M-52.1%	$4.4M-75.0%	$5.2M-51.4%	$6.1M-70.4%	$7.4M-70.6%	$17.6M-41.9%	$10.6M-68.5%	$20.7M-46.8%
Current Assets	$3.5M-52.1%	$4.4M-69.6%	$5.2M-29.2%	$6.1M-42.8%	$7.4M-47.1%	$14.5M-19.2%	$7.3M-64.2%	$10.7M-56.1%
Cash & Equivalents	$3.5M-52.4%	$4.4M-51.3%	$5.1M+198.9%	$6.1M+55.6%	$7.3M-2.4%	$8.9M-19.5%	$1.7M-87.1%	$3.9M-78.3%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	$1.3M-16.2%	$1.4M-43.8%
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	$416K-81.3%	$1.9M-34.5%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$2.8M-3.6%	$2.6M-90.4%	$2.3M-87.3%	$2.8M-84.3%	$2.9M-81.5%	$27.2M+38.6%	$18.1M-15.1%	$17.6M-44.8%
Current Liabilities	$2.8M-3.6%	$2.6M-90.3%	$2.3M-87.3%	$2.8M-78.0%	$2.9M-70.4%	$27.1M+141.8%	$18.0M+67.4%	$12.6M+55.4%
Non-Current Liabilities	$0	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%	$58K-99.3%	$75K-99.3%	$5.0M-78.9%
Total Equity	$701K-84.2%	$1.8M+118.5%	$2.9M+138.4%	$3.4M+8.1%	$4.4M-44.9%	-$9.6M-197.9%	-$7.5M-161.9%	$3.1M-55.1%
Retained Earnings	-$113.2M-2.9%	-$112.3M+2.8%	-$111.3M+1.7%	-$111.0M-6.8%	-$110.0M-8.2%	-$115.5M-14.3%	-$113.2M-14.5%	-$103.9M-4.8%

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

PTPI Cash Flow Statement

PTPI quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Operating Cash Flow	-$3.7M	-$6.7M-158.7%	-$2.6M+65.9%	-$7.6M+40.4%	-$12.8M-7.9%	-$11.9M+22.5%	-$15.3M
Depreciation & Amortization	N/A	N/A	$2.8M-13.8%	$3.3M-41.4%	$5.6M-18.6%	$6.9M+3.3%	$6.7M
Stock-Based Compensation	N/A	$305K+54.5%	$197K-52.7%	$417K-65.1%	$1.2M-8.4%	$1.3M	N/A
Capital Expenditures	N/A	N/A	$25K	N/A	N/A	N/A	$5K
Free Cash Flow	N/A	N/A	-$2.6M	N/A	N/A	N/A	-$15.3M
Investing Cash Flow	N/A	N/A	-$25K	N/A	N/A	N/A	-$5K
Financing Cash Flow	N/A	$8.2M+216.6%	-$7.0M-160.7%	$11.5M+810.4%	-$1.6M-108.7%	$18.6M-38.7%	$30.3M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$864K+71.3%	-$784K+52.8%	-$934K-196.7%	-$1.1M-47.0%	-$3.0M-80.9%	-$1.7M-46.3%	$965K+142.7%	-$771K+80.9%
Depreciation & Amortization	N/A	N/A	N/A	N/A	N/A	N/A	$656K-18.3%	$739K-10.6%
Stock-Based Compensation	N/A	$120K+50.3%	N/A	N/A	N/A	$80K-55.6%	N/A	$0-100.0%
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	$5K	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	$960K	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	-$5K	N/A
Financing Cash Flow	N/A	N/A	$0+100.0%	-$117K+95.8%	-$428K+78.1%	$8.7M+876.4%	-$1.1M+51.8%	-$2.8M-119.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

PTPI Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PTPI quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Gross Margin	N/A	76.3%+4.3pp	72.0%+10.2pp	61.8%-17.7pp	79.5%+21.9pp	57.7%
Operating Margin	N/A	-90.5%	-233.9%	-332.4%	-231.1%	-180.8%
Net Margin	N/A	-280.1%	-140.2%	-334.4%	-115.1%	-215.4%
Return on Equity	66.7%	N/A	-67.6%+52.3pp	-120.0%-94.7pp	-25.3%+92.6pp	-117.8%
Return on Assets	37.1%+171.7pp	-134.6%-110.5pp	-24.1%+37.6pp	-61.8%-48.5pp	-13.3%+16.1pp	-29.5%
Current Ratio	2.25+1.8x	0.40-1.5x	1.89-0.2x	2.08+1.1x	0.99+0.4x	0.62
Debt-to-Equity	0.80	N/A	1.77+0.8x	0.940.0x	0.90-2.1x	3.00
Asset Turnover	N/A	0.48+0.3x	0.170.0x	0.18+0.1x	0.120.0x	0.14
FCF Margin	N/A	-51.4%	N/A	N/A	N/A	-160.2%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	63.5%	81.8%+6.2pp
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	-79.6%	-76.0%
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	-1278.4%	-140.9%
Return on Equity	-136.3%-258.5pp	-55.7%	N/A	-27.4%+43.9pp	122.2%+130.4pp	N/A	N/A	-71.3%-5.6pp
Return on Assets	-27.0%-100.4pp	-22.5%-9.6pp	N/A	-15.0%-4.3pp	73.5%+76.1pp	-12.8%-5.7pp	-87.2%	-10.7%+1.0pp
Current Ratio	1.25-1.3x	1.68+1.1x	2.25+1.8x	2.22+1.4x	2.51+1.1x	0.53-1.1x	0.40-1.5x	0.85-2.2x
Debt-to-Equity	4.06+3.4x	1.48	0.80	0.82-4.8x	0.66-1.3x	N/A	N/A	5.64+1.0x
Asset Turnover	N/A	N/A	N/A	N/A	N/A	N/A	0.07	0.080.0x
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	132.3%	N/A

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Petros Pharmaceuticals Inc PTPI	FY2025	N/A	$1.9M	N/A	$280K	—
Panacea Life Sciences Hldgs Inc PLSH	FY2023	$2.4M	-$8.0M	N/A	$2.1M	—

Where Petros Pharmaceuticals Inc Ranks

Frequently Asked Questions

Is Petros Pharmaceuticals Inc profitable?

Yes, Petros Pharmaceuticals Inc (PTPI) reported a net income of $1.9M in fiscal year 2025.

What is Petros Pharmaceuticals Inc's return on equity (ROE)?

Petros Pharmaceuticals Inc (PTPI) has a return on equity of 66.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Petros Pharmaceuticals Inc's operating cash flow?

Petros Pharmaceuticals Inc (PTPI) recorded an outflow of $6.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Petros Pharmaceuticals Inc's total assets?

Petros Pharmaceuticals Inc (PTPI) had $5.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does Petros Pharmaceuticals Inc have outstanding?

Petros Pharmaceuticals Inc (PTPI) had 42M shares outstanding as of fiscal year 2025.

What is Petros Pharmaceuticals Inc's current ratio?

Petros Pharmaceuticals Inc (PTPI) had a current ratio of 2.25 as of fiscal year 2025, which is generally considered healthy.

What is Petros Pharmaceuticals Inc's debt-to-equity ratio?

Petros Pharmaceuticals Inc (PTPI) had a debt-to-equity ratio of 0.80 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Petros Pharmaceuticals Inc's return on assets (ROA)?

Petros Pharmaceuticals Inc (PTPI) had a return on assets of 37.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Petros Pharmaceuticals Inc's P/E ratio?

Petros Pharmaceuticals Inc (PTPI) trades at 0.1x earnings, its market capitalization divided by net income of $1.9M net income, FY2025. The market capitalization is $280K as of Sep 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Petros Pharmaceuticals Inc's price-to-sales ratio?

Petros Pharmaceuticals Inc (PTPI) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $280K as of Sep 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Petros Pharmaceuticals Inc's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Petros Pharmaceuticals Inc (PTPI) held $5.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $6.7M over that year. Dividing the one by the other, the reported balance equals about 9 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Petros Pharmaceuticals Inc's Piotroski F-Score?

Petros Pharmaceuticals Inc (PTPI) has a Piotroski F-Score of 4 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Petros Pharmaceuticals Inc's earnings high quality?

For every $1 of reported earnings, Petros Pharmaceuticals Inc (PTPI) used $3.52 of operating cash (-$6.7M OCF vs $1.9M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Petros Pharmaceuticals Inc cover its interest payments?

Petros Pharmaceuticals Inc (PTPI) reported an operating loss of $4.6M against $257K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.